BIOCOM AG's articles Biotechnology Rentschler doubles cGMP capacity – European Biotechnology In the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA. According to a company spokesperson, the expansion in the main market for biopharmaceuticals doubles Rentschler’s cGMP-compliant production capacity in one fell swoop. Production for a long-standing client at […] Written by BIOCOM AG July 12, 2024July 12, 2024 Saving Bookmark this article Bookmarked Biotechnology No more needles – Exvolvo arises with help of Verily and NLC Health NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech company providing the next-generation solution for biologic drug delivery as oral administration. NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with […] Written by BIOCOM AG June 25, 2024June 25, 2024 Saving Bookmark this article Bookmarked Biotechnology ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11 ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11. Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek. BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne participated in the financing that will be used to […] Written by BIOCOM AG June 9, 2024June 9, 2024 Saving Bookmark this article Bookmarked Biotechnology AstraZeneca puts step into obesity market Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc. SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a two-year […] Written by BIOCOM AG May 23, 2024May 23, 2024 Saving Bookmark this article Bookmarked Biotechnology AmphiStar BV secures €6m to develop manufacturing Waste primarily based biosurfactants producer Amphistar BV has closed a €6m funding spherical led by the European Round Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF). The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart industrial biosurfactant manufacturing in collaboration with exterior companions. […] Written by BIOCOM AG April 22, 2024April 22, 2024 Saving Bookmark this article Bookmarked Biotechnology New legislation to hurry up medical trials With a brand new legislation, the German authorities desires to extend the variety of medical trials carried out in Germany and make the nation primary in Europe once more. The draft Medical Analysis Act (Medizinforschungsgesetz) introduced by Well being Minister Karl Lauterbach in Berlin earlier than Easter is the centrepiece of Germany’s pharmaceutical technique. With […] Written by BIOCOM AG April 1, 2024April 1, 2024 Saving Bookmark this article Bookmarked Biotechnology AMR: Partnership set to improve in vivo antibiotics testing The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing. The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack of development incentives. Another […] Written by BIOCOM AG November 16, 2023November 16, 2023 Saving Bookmark this article Bookmarked Biotechnology Recordbreaking BIO-Europe in Munich, but: back to 2019 The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already the largest European partnering event for biotech and pharma. However, many other figures are currently pointing back to 2019. Record figures and a much better […] Written by BIOCOM AG November 11, 2023November 11, 2023 Saving Bookmark this article Bookmarked Biotechnology Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond. Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment of adult and pediatric patients two years of age and older with relapsed or […] Written by BIOCOM AG November 6, 2023November 6, 2023 Saving Bookmark this article Bookmarked Biotechnology Cellectis and AstraZeneca in US$2.2bn deal AstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies. Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca plc into Cellectis […] Written by BIOCOM AG November 1, 2023November 1, 2023 Saving Bookmark this article Bookmarked Biotechnology BioNtech reports Car-T/mRNA booster study results at ESMO BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid Testing different dose levels of its adoptive cell therapy BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted Car-T cells (derived from NEO-PTC-01, initially developed by tody’s BioNTech subsidiary Neon Therapeutics) and the mRNA-based Car-T booster CarVac (CAR-T cell […] Written by BIOCOM AG October 27, 2023October 27, 2023 Saving Bookmark this article Bookmarked Biotechnology Antiverse and GlobalBio Inc. extend collaboration Antiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy. The initial collaboration successfully resulted in the generation […] Written by BIOCOM AG October 21, 2023October 21, 2023 Saving Bookmark this article Bookmarked Loading Load more
Biotechnology Rentschler doubles cGMP capacity – European Biotechnology In the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA. According to a company spokesperson, the expansion in the main market for biopharmaceuticals doubles Rentschler’s cGMP-compliant production capacity in one fell swoop. Production for a long-standing client at […] Written by BIOCOM AG July 12, 2024July 12, 2024 Saving Bookmark this article Bookmarked
Biotechnology No more needles – Exvolvo arises with help of Verily and NLC Health NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech company providing the next-generation solution for biologic drug delivery as oral administration. NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with […] Written by BIOCOM AG June 25, 2024June 25, 2024 Saving Bookmark this article Bookmarked
Biotechnology ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11 ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11. Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek. BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne participated in the financing that will be used to […] Written by BIOCOM AG June 9, 2024June 9, 2024 Saving Bookmark this article Bookmarked
Biotechnology AstraZeneca puts step into obesity market Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc. SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a two-year […] Written by BIOCOM AG May 23, 2024May 23, 2024 Saving Bookmark this article Bookmarked
Biotechnology AmphiStar BV secures €6m to develop manufacturing Waste primarily based biosurfactants producer Amphistar BV has closed a €6m funding spherical led by the European Round Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF). The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart industrial biosurfactant manufacturing in collaboration with exterior companions. […] Written by BIOCOM AG April 22, 2024April 22, 2024 Saving Bookmark this article Bookmarked
Biotechnology New legislation to hurry up medical trials With a brand new legislation, the German authorities desires to extend the variety of medical trials carried out in Germany and make the nation primary in Europe once more. The draft Medical Analysis Act (Medizinforschungsgesetz) introduced by Well being Minister Karl Lauterbach in Berlin earlier than Easter is the centrepiece of Germany’s pharmaceutical technique. With […] Written by BIOCOM AG April 1, 2024April 1, 2024 Saving Bookmark this article Bookmarked
Biotechnology AMR: Partnership set to improve in vivo antibiotics testing The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing. The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack of development incentives. Another […] Written by BIOCOM AG November 16, 2023November 16, 2023 Saving Bookmark this article Bookmarked
Biotechnology Recordbreaking BIO-Europe in Munich, but: back to 2019 The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already the largest European partnering event for biotech and pharma. However, many other figures are currently pointing back to 2019. Record figures and a much better […] Written by BIOCOM AG November 11, 2023November 11, 2023 Saving Bookmark this article Bookmarked
Biotechnology Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond. Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment of adult and pediatric patients two years of age and older with relapsed or […] Written by BIOCOM AG November 6, 2023November 6, 2023 Saving Bookmark this article Bookmarked
Biotechnology Cellectis and AstraZeneca in US$2.2bn deal AstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies. Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca plc into Cellectis […] Written by BIOCOM AG November 1, 2023November 1, 2023 Saving Bookmark this article Bookmarked
Biotechnology BioNtech reports Car-T/mRNA booster study results at ESMO BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid Testing different dose levels of its adoptive cell therapy BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted Car-T cells (derived from NEO-PTC-01, initially developed by tody’s BioNTech subsidiary Neon Therapeutics) and the mRNA-based Car-T booster CarVac (CAR-T cell […] Written by BIOCOM AG October 27, 2023October 27, 2023 Saving Bookmark this article Bookmarked
Biotechnology Antiverse and GlobalBio Inc. extend collaboration Antiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy. The initial collaboration successfully resulted in the generation […] Written by BIOCOM AG October 21, 2023October 21, 2023 Saving Bookmark this article Bookmarked
